Mar 145 minPositive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint metFirst-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years...
May 5, 20202 minAcesion Pharma Strengthens Clinical Team with Key Appointments Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation (AF), the most common cardiac...
Mar 12, 20192 minAcesion Pharma receives 5M DKK from Innovation Fund Denmark to support human Proof-of-Concept study Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most...